Non-small-cell Lung Cancer
Conditions
Interventions
Gold Standard:The EGFR T790M mutation detected by the human EGFR gene mutation detection kit (fluorescent PCR method) produced by Xiamen Aide Biomedical Technology Co., Ltd.
Index test:The 
T790M 
by 
the 
detection 
kit 
(digital 
Nanjing 
Covis 
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically confirmed advanced non-small cell lung cancer; 2) Specific samples: small cell lung cancer and benign lung tumors; 3) Available peripheral blood plasma sample of non-small cell lung cancer patients ; 4) Available homologous tissue samples are the remaining paraffin-embedded tissue samples collected during the same period (within four weeks before and after the blood sampling) of the patient's plasma samples; 5) Subjects voluntarily participate in this study and sign an informed consent form. Note: The selected samples must meet the above 1) or 2) and meet the standards of 3) and 5); 4) is collected according to the actual situation.
Exclusion criteria
Exclusion criteria: 1) The time of sample collection or case information is not clear; 2) Those with insufficient sample size for testing; 3) Those who meet the selection criteria, but the researcher thinks they are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive coincidence rate;Negative coincidence rate;The total coincidence rate;Kappa value; | — |
Countries
China
Contacts
Public ContactJie Wang
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed